Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

Vista sencilla de ítem
dc.contributor.authorGálvez, Nicolás M. S.
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorSchultz, Bárbara M.
dc.contributor.authorMelo-González, Felipe
dc.contributor.authorSoto, Jorge A.
dc.contributor.authorDuarte, Luisa F.
dc.contributor.authorGonzález, Liliana A.
dc.contributor.authorRivera-Pérez, Daniela
dc.contributor.authorRíos, Mariana
dc.contributor.authorBerrios, Roslye V.
dc.contributor.authorVázquez, Yaneisi
dc.contributor.authorMoreno-Tapia, Daniela
dc.contributor.authorVallejos, Omar P.
dc.contributor.authorAndrade, Catalina A.
dc.contributor.authorHoppe-Elsholz, Guillermo
dc.contributor.authorIturriaga, Carolina
dc.contributor.authorUrzua, Marcela
dc.contributor.authorNavarrete, María S.
dc.contributor.authorRojas, Álvaro
dc.contributor.authorFasce, Rodrigo
dc.contributor.authorFernández, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamírez, Eugenio
dc.contributor.authorGaete-Argel, Aracelly
dc.contributor.authorAcevedo, Mónica L.
dc.contributor.authorValiente-Echeverría, Fernando
dc.contributor.authorSoto-Rifo, Ricardo
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorGrifoni, Alba
dc.contributor.authorSette, Alessandro
dc.contributor.authorZeng, Gang
dc.contributor.authorMeng, Weining
dc.contributor.authorGonzález-Aramundiz, José V.
dc.contributor.authorJohnson, Marina
dc.contributor.authorGoldblatt, David
dc.contributor.authorGonzález, Pablo A.
dc.contributor.authorAbarca, Katia
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2024-10-02T13:46:51Z
dc.date.available2024-10-02T13:46:51Z
dc.date.issued2022
dc.descriptionIndexación: Scopus.
dc.description.abstractBackground: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile. Methods: This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean adults aged ≥18 years. Volunteers received two doses of CoronaVac separated by 2 (0–14 schedule) or 4 weeks (0–28 schedule); 2302 volunteers were enrolled, 440 were part of the immunogenicity arm, and blood samples were obtained at different times. Samples from a single center are reported. Humoral immune responses were evaluated by measuring the neutralizing capacities of circulating antibodies. Cellular immune responses were assessed by ELISPOT and flow cytometry. Correlation matrixes were performed to evaluate correlations in the data measured. Results: Both schedules exhibited robust neutralizing capacities with the response induced by the 0–28 schedule being better. No differences were found in the concentration of antibodies against the virus and different variants of concern (VOCs) between schedules. Stimulation of peripheral blood mononuclear cells (PBMCs) with Mega pools of Peptides (MPs) induced the secretion of interferon (IFN)-γ and the expression of activation induced markers in CD4+ T cells for both schedules. Correlation matrixes showed strong correlations between neutralizing antibodies and IFN-γ secretion. Conclusions: Immunization with CoronaVac in Chilean adults promotes robust cellular and humoral immune responses. The 0–28 schedule induced a stronger humoral immune response than the 0–14 schedule. © Gálvez, Pacheco, Schultz et al.
dc.description.urihttps://elifesciences.org/articles/81477#copyright
dc.identifier.citationeLifeOpen AccessVolume 112022 Article number e81477
dc.identifier.doi10.7554/eLife.81477
dc.identifier.issn2050-084X
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/60702
dc.language.isoen
dc.publishereLife Sciences Publications Ltd
dc.rights.licenseAttribution 4.0 International CC BY 4.0 Deed
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCD134 antigen
dc.subjectCD69 antigen
dc.subjectCoronavac
dc.subjectGamma interferon
dc.subjectImmunoglobulin G
dc.subjectInterleukin 4
dc.subjectNeutralizing antibody
dc.subjectSARS-CoV-2 antibody
dc.subjectTumor necrosis factor receptor superfamily member 9
dc.titleDifferences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Galvez_Differences_in_the_immune_response.pdf
Tamaño:
2.52 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Colecciones
Fac.CV - Artículos de Revista